130 related articles for article (PubMed ID: 8931121)
1. Cerebrodiene, arachidonyl-ethanolamide, and hybrid structures: potential for interaction with brain cannabinoid receptors.
Boring DL; Berglund BA; Howlett AC
Prostaglandins Leukot Essent Fatty Acids; 1996 Sep; 55(3):207-10. PubMed ID: 8931121
[TBL] [Abstract][Full Text] [Related]
2. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
Lin S; Khanolkar AD; Fan P; Goutopoulos A; Qin C; Papahadjis D; Makriyannis A
J Med Chem; 1998 Dec; 41(27):5353-61. PubMed ID: 9876105
[TBL] [Abstract][Full Text] [Related]
3. Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups.
Berglund BA; Boring DL; Wilken GH; Makriyannis A; Howlett AC; Lin S
Prostaglandins Leukot Essent Fatty Acids; 1998 Aug; 59(2):111-8. PubMed ID: 9774174
[TBL] [Abstract][Full Text] [Related]
4. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
van der Stelt M; van Kuik JA; Bari M; van Zadelhoff G; Leeflang BR; Veldink GA; Finazzi-Agrò A; Vliegenthart JF; Maccarrone M
J Med Chem; 2002 Aug; 45(17):3709-20. PubMed ID: 12166944
[TBL] [Abstract][Full Text] [Related]
5. The binding of novel phenolic derivatives of anandamide to brain cannabinoid receptors.
Edgemond WS; Campbell WB; Hillard CJ
Prostaglandins Leukot Essent Fatty Acids; 1995; 52(2-3):83-6. PubMed ID: 7784462
[TBL] [Abstract][Full Text] [Related]
6. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain.
Sugiura T; Kondo S; Sukagawa A; Nakane S; Shinoda A; Itoh K; Yamashita A; Waku K
Biochem Biophys Res Commun; 1995 Oct; 215(1):89-97. PubMed ID: 7575630
[TBL] [Abstract][Full Text] [Related]
7. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol.
Hillard CJ
Prostaglandins Other Lipid Mediat; 2000 Apr; 61(1-2):3-18. PubMed ID: 10785538
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological and behavioral evaluation of alkylated anandamide analogs.
Adams IB; Ryan W; Singer M; Razdan RK; Compton DR; Martin BR
Life Sci; 1995; 56(23-24):2041-8. PubMed ID: 7776830
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs.
Adams IB; Ryan W; Singer M; Thomas BF; Compton DR; Razdan RK; Martin BR
J Pharmacol Exp Ther; 1995 Jun; 273(3):1172-81. PubMed ID: 7791088
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cannabimimetic effects of structural analogs of anandamide in rats.
Wiley JL; Ryan WJ; Razdan RK; Martin BR
Eur J Pharmacol; 1998 Aug; 355(2-3):113-8. PubMed ID: 9760024
[TBL] [Abstract][Full Text] [Related]
11. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand.
Khanolkar AD; Abadji V; Lin S; Hill WA; Taha G; Abouzid K; Meng Z; Fan P; Makriyannis A
J Med Chem; 1996 Oct; 39(22):4515-9. PubMed ID: 8893848
[TBL] [Abstract][Full Text] [Related]
12. Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid.
Hillard CJ; Campbell WB
J Lipid Res; 1997 Dec; 38(12):2383-98. PubMed ID: 9458263
[TBL] [Abstract][Full Text] [Related]
13. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.
Felder CC; Briley EM; Axelrod J; Simpson JT; Mackie K; Devane WA
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7656-60. PubMed ID: 8395053
[TBL] [Abstract][Full Text] [Related]
14. Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]Thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats.
Rubino T; Viganò D; Costa B; Colleoni M; Parolaro D
J Neurochem; 2000 Dec; 75(6):2478-84. PubMed ID: 11080200
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel cannabinoid receptor ligands from diverse marine organisms.
Soderstrom K; Murray TF; Yoo HD; Ketchum S; Milligan K; Gerwick W; Ortega MJ; Salva J
Adv Exp Med Biol; 1997; 433():73-7. PubMed ID: 9561107
[No Abstract] [Full Text] [Related]
16. Biochemistry of the endogenous ligands of cannabinoid receptors.
Di Marzo V; Deutsch DG
Neurobiol Dis; 1998 Dec; 5(6 Pt B):386-404. PubMed ID: 9974173
[TBL] [Abstract][Full Text] [Related]
17. Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
Devane WA; Hanus L; Breuer A; Pertwee RG; Stevenson LA; Griffin G; Gibson D; Mandelbaum A; Etinger A; Mechoulam R
Science; 1992 Dec; 258(5090):1946-9. PubMed ID: 1470919
[TBL] [Abstract][Full Text] [Related]
18. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide.
Jonsson KO; Vandevoorde S; Lambert DM; Tiger G; Fowler CJ
Br J Pharmacol; 2001 Aug; 133(8):1263-75. PubMed ID: 11498512
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of leukocyte function and interleukin-2 gene expression by 2-methylarachidonyl-(2'-fluoroethyl)amide, a stable congener of the endogenous cannabinoid receptor ligand anandamide.
Kaplan BL; Ouyang Y; Herring A; Yea SS; Razdan R; Kaminski NE
Toxicol Appl Pharmacol; 2005 Jun; 205(2):107-15. PubMed ID: 15893538
[TBL] [Abstract][Full Text] [Related]
20. Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor.
Hampson AJ; Hill WA; Zan-Phillips M; Makriyannis A; Leung E; Eglen RM; Bornheim LM
Biochim Biophys Acta; 1995 Nov; 1259(2):173-9. PubMed ID: 7488638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]